|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
GB9125768D0
(en)
*
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
|
GB9603507D0
(en)
*
|
1996-02-20 |
1996-04-17 |
Isis Innovation |
Antibody variants
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US20060057107A1
(en)
*
|
2001-12-21 |
2006-03-16 |
Shaked Ze Ev |
Combination treatment for multiple sclerosis
|
|
WO2003067221A2
(en)
|
2002-02-08 |
2003-08-14 |
Xcyte Therapies, Inc. |
Compositions and methods for restoring immune responsiveness in patients with immunological defects
|
|
ES2422193T3
(es)
|
2002-06-28 |
2013-09-09 |
Life Technologies Corp |
Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
|
|
US20040224402A1
(en)
*
|
2003-05-08 |
2004-11-11 |
Xcyte Therapies, Inc. |
Generation and isolation of antigen-specific T cells
|
|
EP1663308A1
(de)
*
|
2003-09-22 |
2006-06-07 |
Xcyte Therapies, Inc |
Zusammensetzungen und verfahren zur beschleunigung der hämatologischen erholung
|
|
CN1898267B
(zh)
|
2003-11-01 |
2012-05-23 |
默克专利股份有限公司 |
修饰的抗cd52抗体
|
|
CA2649296A1
(en)
|
2006-04-13 |
2007-10-25 |
Peptimmune, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
|
EP1854810A1
(de)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
De-immunisierter und antagonister monoclonaler Antikörper gegen CD40, der aus der ch5D12 Antikörper abgeleitet ist
|
|
HUE026740T2
(en)
|
2006-09-13 |
2016-07-28 |
Alcafleu Man Gmbh & Co Kg |
Treatment of Multiple Sclerosis (MS) with Campath-1H
|
|
US9498528B2
(en)
|
2006-09-13 |
2016-11-22 |
Genzyme Corporation |
Treatment of multiple sclerosis (MS)
|
|
PL2130044T3
(pl)
|
2007-02-16 |
2017-04-28 |
Genzyme Corporation |
Sposób identyfikowania ryzyka rozwoju chorób tarczycy
|
|
EP3456733A1
(de)
*
|
2007-05-11 |
2019-03-20 |
Genzyme Corporation |
Verfahren zur herstellung eines sekretierten proteins
|
|
EP2429583A4
(de)
|
2009-05-13 |
2013-10-16 |
Genzyme Corp |
Verfahren und zusammensetzungen zur lupus-behandlung
|
|
MY160126A
(en)
*
|
2009-05-13 |
2017-02-28 |
Genzyme Corp |
Anti-human cd52 immunoglobulins
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CA3179835A1
(en)
|
2011-01-18 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
US10981969B2
(en)
|
2011-07-29 |
2021-04-20 |
The Trustees Of The University Of Pennsylvania |
Switch costimulatory receptors
|
|
EA201490636A1
(ru)
|
2011-09-16 |
2014-08-29 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
ES2861435T3
(es)
|
2011-11-03 |
2021-10-06 |
Univ Pennsylvania |
Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
|
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
|
US9783591B2
(en)
|
2012-02-22 |
2017-10-10 |
The Trustees Of The University Of Pennsylvania |
Use of the CD2 signaling domain in second-generation chimeric antigen receptors
|
|
JP2015509717A
(ja)
|
2012-02-22 |
2015-04-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用
|
|
EP2872533B1
(de)
|
2012-07-13 |
2019-04-24 |
The Trustees Of The University Of Pennsylvania |
Verfahren zur beurteilung der eignung von transduzierten t-zellen zur verabreichung
|
|
LT2872171T
(lt)
|
2012-07-13 |
2021-04-26 |
The Trustees Of The University Of Pennsylvania |
Car priešnavikinio aktyvumo toksiškumo reguliavimas
|
|
EP2872526B1
(de)
|
2012-07-13 |
2020-04-01 |
The Trustees of the University of Pennsylvania |
Verstärkung der aktivität von car-t-zellen durch miteinführung eines bispezifischen antikörpers
|
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
|
HK1220205A1
(zh)
*
|
2013-03-15 |
2017-04-28 |
Celgene Corporation |
修饰的t淋巴细胞
|
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
|
PL3888674T3
(pl)
|
2014-04-07 |
2024-09-23 |
Novartis Ag |
Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
|
|
US10301370B2
(en)
|
2014-05-02 |
2019-05-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor T cells
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3722316A1
(de)
|
2014-07-21 |
2020-10-14 |
Novartis AG |
Behandlung von krebs unter verwendung eines chimären cd33-antigenrezeptors
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
CN107206024B
(zh)
|
2014-10-31 |
2021-12-03 |
宾夕法尼亚大学董事会 |
改变cart细胞中的基因表达及其用途
|
|
AU2015338984A1
(en)
|
2014-10-31 |
2017-04-27 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified T cells
|
|
AU2015339106B2
(en)
|
2014-10-31 |
2020-07-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of stimulating and expanding T cells
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
CA2975147C
(en)
|
2015-01-31 |
2025-06-10 |
The Trustees Of The University Of Pennsylvania |
COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US10414812B2
(en)
|
2015-02-16 |
2019-09-17 |
The Trustees Of The University Of Pennsylvania |
Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
|
|
KR102133857B1
(ko)
|
2015-03-02 |
2020-07-20 |
이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 |
Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소
|
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
IL303905A
(en)
|
2015-05-18 |
2023-08-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR programming using fusion proteins
|
|
CN107849148B
(zh)
|
2015-05-21 |
2023-09-19 |
哈普恩治疗公司 |
三特异性结合蛋白质及使用方法
|
|
US11890301B2
(en)
|
2015-08-28 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
EP4218777A3
(de)
|
2015-08-28 |
2023-08-23 |
The Trustees of the University of Pennsylvania |
Verfahren und zusammensetzungen für zellen, die ein chimäres intrazelluläres signalmolekül exprimieren
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
WO2017059796A1
(en)
|
2015-10-08 |
2017-04-13 |
Shanghai Sidansai Biotechnology Co., Ltd |
Activation and expansion of t cells
|
|
PL3380620T3
(pl)
|
2015-11-23 |
2024-11-12 |
Novartis Ag |
Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie
|
|
EP3393504B1
(de)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin-spezifischer chimärischer antigenrezeptor (car) und antikörper gegen pd-l1zur kombinierten verwendung bei therapie gegen krebs
|
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3432924A1
(de)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Zellsekretierte minikörper und verwendungen davon
|
|
WO2017167217A1
(en)
|
2016-04-01 |
2017-10-05 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
|
RU2018140056A
(ru)
|
2016-04-15 |
2020-05-15 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
KR20190057275A
(ko)
|
2016-07-18 |
2019-05-28 |
헬릭스 바이오파마 코포레이션 |
암을 치료하기 위한 암배아 항원 관련 세포 부착 분자 6에 대한 car 면역 세포
|
|
JP7109789B2
(ja)
|
2016-08-02 |
2022-08-01 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
|
|
ES2875959T3
(es)
|
2016-10-07 |
2021-11-11 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
|
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CA3044729A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
WO2018098354A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
EP3558348A1
(de)
|
2016-12-21 |
2019-10-30 |
TCR2 Therapeutics Inc. |
Manipulierte t-zellen zur behandlung von krebs
|
|
CN116120454A
(zh)
|
2017-01-05 |
2023-05-16 |
上海煦顼技术有限公司 |
人源化抗cd19抗体及其与嵌合抗原受体的用途
|
|
EP3589662A4
(de)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
Induzierbares monovalentes antigenbindendes protein
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
CN113896792B
(zh)
|
2017-05-12 |
2025-08-22 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
EP3621648A4
(de)
|
2017-05-12 |
2021-01-20 |
Harpoon Therapeutics, Inc. |
Auf trispezifische proteine abzielendes msln und verfahren zur verwendung
|
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR20200063215A
(ko)
|
2017-10-06 |
2020-06-04 |
오슬로 유니버시테시케후스 에이치에프 |
키메라 항원 수용체
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
KR102425983B1
(ko)
|
2017-10-13 |
2022-07-29 |
하푼 테라퓨틱스, 인크. |
삼중특이적 단백질 및 사용 방법
|
|
TW201922774A
(zh)
|
2017-11-15 |
2019-06-16 |
瑞士商諾華公司 |
標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法
|
|
WO2019129851A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Method for improving production of car t cells
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US12215154B2
(en)
|
2018-01-19 |
2025-02-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting γδ T cells with chimeric antigen receptors
|
|
EP3746116A1
(de)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Kombinationstherapie unter verwendung eines chimären antigenrezeptors
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20210095001A1
(en)
|
2018-05-02 |
2021-04-01 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
WO2019236593A1
(en)
|
2018-06-05 |
2019-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
WO2019241549A1
(en)
|
2018-06-15 |
2019-12-19 |
A2 Biotherapeutics, Inc. |
Foxp3-expressing car-t regulatory cells
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
MX2021001763A
(es)
|
2018-08-13 |
2021-04-19 |
Rootpath Genomics Inc |
Clonacion de alto rendimiento de polinucleotidos inmunoreceptores bipartitas emparejados y aplicaciones de los mismos.
|
|
CA3110565A1
(en)
|
2018-08-30 |
2020-03-05 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
IL281683B2
(en)
|
2018-09-25 |
2023-04-01 |
Harpoon Therapeutics Inc |
dll3 binding proteins and methods of use
|
|
EP3856782A1
(de)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Chimärer cd19-antigen-rezeptor (car) und cd22-car-kombinationstherapien
|
|
EP3856779A1
(de)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Chimäre cd22-antigen-rezeptor(car)-therapien
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
IL285909B2
(en)
|
2019-03-15 |
2023-04-01 |
Cartesian Therapeutics Inc |
Single-stranded variable segments directed against bcma
|
|
CA3135850A1
(en)
|
2019-04-05 |
2020-10-08 |
Rootpath Genomics, Inc. |
Compositions and methods for t-cell receptor gene assembly
|
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
BR112022009679A2
(pt)
|
2019-11-26 |
2022-08-09 |
Novartis Ag |
Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
IL298693A
(en)
|
2020-06-04 |
2023-02-01 |
Carisma Therapeutics Inc |
New structures for chimeric antigen receptors
|
|
AU2021288224A1
(en)
|
2020-06-11 |
2023-01-05 |
Novartis Ag |
ZBTB32 inhibitors and uses thereof
|
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
|
|
CN119677842A
(zh)
|
2022-03-17 |
2025-03-21 |
科士华(南京)生物技术有限公司 |
人工合成肿瘤浸润淋巴细胞
|
|
WO2024133052A1
(en)
|
2022-12-19 |
2024-06-27 |
Universität Basel Vizerektorat Forschung |
T-cell receptor fusion protein
|